Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
NCT06000033
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Disitamab Vedotin+Anlotinib
Sponsor
Qilu Hospital of Shandong University